ACE Technology Guidances

ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 20 Dec 2021
Last Updated on 20 Dec 2021
A- A+
Guidance Recommendation

The Ministry of Health’s MTAC has recommended subsidy for antibacterial envelope for the prevention of cardiac implantable electronic device (CIED)-related infections in:

  • Patients deemed to be at high risk of CIED-related infections based on:
    • Patient-related risk factors such as end-stage renal disease, corticosteroid use, renal failure, history of device infection, chronic obstructive pulmonary disease (COPD), >New York Heart Association (NYHA) class II heart failure, malignancy, diabetes mellitus, fever prior to implantation, skin disorders, heparin bridging, and oral anticoagulants; OR
    • Procedure-related risk factors such as device replacement, revision or upgrade, generator replacement, and lead repositioning; OR
    • Device-related risk factors such as use of implantable cardioverter defibrillators (ICD), cardiac resynchronisation therapy - defibrillators (CRT-D), epicardial leads, abdominal pockets, and ≥2 leads.
  • Patients receiving permanent pacemakers and cardiac resynchronisation therapy – pacemakers (CRT-P) if they have other high-risk factors for CIED infection.

Subsidy status

Antibacterial envelope is recommended for inclusion in the Medical Technology Subsidy List (MTSL) for the abovementioned indication(s) only.


Antibacterial envelope for the prevention of cardiac implantable electronic device-related infections